AU1971899A - Use of citrulline peptides derived from filaggrin for treating autoimmune diseases - Google Patents

Use of citrulline peptides derived from filaggrin for treating autoimmune diseases

Info

Publication number
AU1971899A
AU1971899A AU19718/99A AU1971899A AU1971899A AU 1971899 A AU1971899 A AU 1971899A AU 19718/99 A AU19718/99 A AU 19718/99A AU 1971899 A AU1971899 A AU 1971899A AU 1971899 A AU1971899 A AU 1971899A
Authority
AU
Australia
Prior art keywords
filaggrin
autoimmune diseases
peptides derived
treating autoimmune
citrulline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19718/99A
Inventor
Michel Arnaud
Pascal Dalbon
Elisabeth Girbal-Neuhauser
Michel Jolivet
Colette Jolivet-Reynaud
Mireille Sebbag
Guy Serre
Michel Simon
Christian Vincent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Toulouse III Paul Sabatier
Original Assignee
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Toulouse III Paul Sabatier filed Critical Universite Toulouse III Paul Sabatier
Publication of AU1971899A publication Critical patent/AU1971899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Abstract

The invention concerns the use of a citrulline peptide antigen derived from filaggrin to obtain medicines for treating rheumatoid arthritis.
AU19718/99A 1997-12-30 1998-12-29 Use of citrulline peptides derived from filaggrin for treating autoimmune diseases Abandoned AU1971899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9716672A FR2773078B1 (en) 1997-12-30 1997-12-30 USE OF CITRULLIN PEPTIDES DERIVED FROM FILAGGRIN FOR THE TREATMENT OF RHUMATOID POLYARTHRITIS
FR9716672 1997-12-30
PCT/FR1998/002900 WO1999034819A2 (en) 1997-12-30 1998-12-29 Use of citrulline peptides derived from filaggrin for treating autoimmune diseases

Publications (1)

Publication Number Publication Date
AU1971899A true AU1971899A (en) 1999-07-26

Family

ID=9515271

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19718/99A Abandoned AU1971899A (en) 1997-12-30 1998-12-29 Use of citrulline peptides derived from filaggrin for treating autoimmune diseases

Country Status (10)

Country Link
EP (1) EP1041997B1 (en)
JP (1) JP4557421B2 (en)
AT (1) ATE237345T1 (en)
AU (1) AU1971899A (en)
CA (1) CA2315294C (en)
DE (1) DE69813620T2 (en)
DK (1) DK1041997T3 (en)
ES (1) ES2193601T3 (en)
FR (1) FR2773078B1 (en)
WO (1) WO1999034819A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900657B1 (en) * 2006-05-03 2009-04-17 Univ Toulouse IDENTIFICATION OF MACROPHAGE ACTIVATION MODULATORS, USEFUL FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
FR2908134B1 (en) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier IDENTIFICATION OF MACROPHAGE ACTIVATION MODULATORS, USEFUL FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3307636B2 (en) * 1990-01-31 2002-07-24 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ オクラホマ Assays and treatments for autoimmune diseases
CA2084876A1 (en) * 1991-04-26 1992-10-27 Guy Serre Antigens specifically recognized by specific antibodies of rheumatoid arthritis, their constituent proteins, preparation and applications
AU6098994A (en) * 1993-01-27 1994-08-15 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
FR2752842B1 (en) * 1996-08-30 1998-11-06 Biomerieux Sa ANTIGENS DERIVED FROM FILAGGRINS AND THEIR USE FOR THE DIAGNOSIS OF RHUMATOID POLYARTHRITIS
NL1004539C2 (en) * 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide derived from an antigen recognized by autoantibodies of patients with rheumatoid arthritis, antibody to it and method for detecting autoimmune antibodies.
WO1999028344A2 (en) * 1997-11-28 1999-06-10 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
FR2773157B1 (en) * 1997-12-30 2001-10-05 Bio Merieux PEPTIDE EPITOPES RECOGNIZED BY ANTIFILAGGRIN AUTOANTIBODIES PRESENT IN THE SERUM OF PATIENTS WITH RHUMATOID POLYARTHRITIS

Also Published As

Publication number Publication date
ES2193601T3 (en) 2003-11-01
DE69813620D1 (en) 2003-05-22
DK1041997T3 (en) 2003-08-04
FR2773078B1 (en) 2000-05-26
FR2773078A1 (en) 1999-07-02
DE69813620T2 (en) 2004-02-12
WO1999034819A2 (en) 1999-07-15
CA2315294C (en) 2012-07-03
JP4557421B2 (en) 2010-10-06
JP2002500195A (en) 2002-01-08
ATE237345T1 (en) 2003-05-15
CA2315294A1 (en) 1999-07-15
EP1041997B1 (en) 2003-04-16
EP1041997A2 (en) 2000-10-11
WO1999034819A3 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
HUP0204199A2 (en) Transport vectors
EP0637630A3 (en) Method for the biological synthesis of peptides
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
DE69636450D1 (en) PEPTIDES AND PEPTIDOMIMETICS WITH STRUCTURAL SIMILARITY WITH p53 AND THAT ACTIVATE THE p53 FUNCTION
AU4397297A (en) Antibody against human parathormone related peptides
ZA988585B (en) Pharmaceutical compositions containing plasma protein.
AU7203496A (en) Novel peptides
AU6095696A (en) Immunogenic peptides of prostate specific antigen
PL344534A1 (en) Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
AU8988098A (en) Vectors derived from antibodies for transferring substances into cells
BR9610725A (en) Somatostanin cylindrical peptide analogs
IL135687A0 (en) A novel human checkpoint kinase, hcds1, compositions and methods
ITMI951764A0 (en) ENGINEERED PEPTIDE SYNTHETASES AND THEIR USE FOR THE NON-RIBOSOME PRODUCTION OF PEPTIDES
AU4427296A (en) Novel peptide
AU4394396A (en) Modified peptides
AU8912698A (en) Inhibition of hiv-1 replication using d-amino acid peptides
FR2692282B1 (en) CLONING OF THE GENE ENCODING THE PROTEIN GP28.5 OF T. GONDII; PEPTIDE FRAGMENTS FROM SUCH PROTEIN AND THEIR APPLICATIONS.
AU6804394A (en) Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymeric beads
AU1971799A (en) Peptide epitopes recognised by antifilaggrin autoantibodies in serum from rheumatoid arthritis patients
AU1971899A (en) Use of citrulline peptides derived from filaggrin for treating autoimmune diseases
HUP9901303A3 (en) A pharmaceutical composition for the treatment of autoimmune diseases
HUP9801680A3 (en) Peptides and remedy for autoimmune diseases comprising the same
GR3021660T3 (en) Anticoagulant peptides
ATE207757T1 (en) NOVEL TRIPEPTIDES USABLE FOR IMMUNE AND CNS THERAPY
EP0717752A4 (en) Therapeutic compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase